Orna Schwartz

Dr. Orna Schwartz


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Abed AgbaryaAbed Agbarya
Abed Agbarya
ISIna Sarel
Ina Sarel
TZTomer Ziv-Baran
Tomer Ziv-Baran
SASivan Agranat
Sivan Agranat
OSOrna Schwartz
Orna Schwartz
RBRonen Brenner
Ronen Brenner
The BNT162b2 vaccine was shown to be highly effective in reducing the risk of COVID-19 infection in healthy individuals and patients with chronic disease. However, there are little data regarding its efficacy in patients treated for cancer. We analyzed the humoral response following vaccination with the second dose of BNT162b2 in 140 patients with solid malignancies who were receiving anti-cancer therapy at the time of vaccination and 215 participants who had not been diagnosed with cancer. Multivariate analysis was performed, followed by matching the two groups by age, gender and days from vaccination. The humoral response in the cancer patient group was significantly lower than in the non-cancer group: 20/140 seronegative (14.3%) vs. 3/215 (1.4%), p < 0.001; median IgG levels 2231 AU/mL (IQR 445-8023) vs. 4100 (IQR 2231-6774) p = 0.001 respectively. The odds ratio for negative serology results in cancer patients adjusted by age and gender was 7.35 compared to participants without cancer. This effect was observed only in chemotherapy treated patients: 17/73 seronegative (23.3%) vs. 3/215 (1.4%), p < 0.001; median IgG 1361 AU/mL vs. 4100, p < 0.001 but not in patients treated with non-chemotherapeutic drugs. Reduced immunogenicity to COVID-19 vaccine among chemotherapy-treated cancer patients, raises the need to continue exercising protective measures after vaccination in these patients.

Verified
Journal Article
Open access
PDF file
EBElad Barber
Elad Barber
Michal KovoMichal Kovo
Michal Kovo
SLSophia Leytes
Sophia Leytes
RSRon Sagiv
Ron Sagiv
EWEran Weiner
Eran Weiner
SGShimon Ginath
Shimon Ginath
Objective: We aimed to investigate the likelihood of vaginal colonization with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in pregnant and non-pregnant women with Coronavrus Disease 2019 (COVID-19). Materials and Methods: Vaginal swabs were taken from women diagnosed with mild to moderately acute SARS-CoV-2 infection, at Wolfson Medical Center, Israel, from March 2020 through October 2020. COVID-19 was diagnosed by real-time polymerase chain reaction (RT-PCR) performed on nasopharyngeal swabs. Vaginal swabs were tested for the presence of SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR). Results: In total, 51 women diagnosed with COVID-19 were included in the study. Of the 51 women with COVID-19 enrolled in this study, 16 (31.4%) were pregnant at enrollment and 35 (68.6%) were non-pregnant. Mean age was 43.5 ± 15.3 years (range 21–74 years). Compared to the non-pregnant group, the pregnant group was characterized by a higher white blood cell and absolute neutrophil count (p = 0.02 and p = 0.027, respectively). The non-pregnant patients were more likely to have chronic diseases (p = 0.035) and to be hospitalized (p < 0.001). Only one patient (1.9%) aged 60 years tested positive for SARS-CoV-2 in vaginal secretions. Mean gestational age at the diagnosis of COVID-19 of the pregnant group was 32.3 ± 7.8 weeks. Thirteen patients delivered during the study period; all delivered at term without obstetric complications and all neonates were healthy. Conclusions: Detection of SARS-CoV-2 in the vaginal secretions of patients diagnosed with COVID-19 is rare. Vaginal colonization may occur during the viremia phase of the disease, although infectivity from vaginal colonization needs to be proven.

21 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AHAsher Hackett
Asher Hackett
OYOrit Yossepowitch
Orit Yossepowitch
YGYael Goor
Yael Goor
RSRivka Sheffer
Rivka Sheffer
OSOrna Schwartz
Orna Schwartz
Yasmin MaorYasmin Maor
Yasmin Maor
Background/Objectives: Mycoplasma genitalium (MG) infections and antibiotic resistance are increasing in prevalence while treatment options are limited. Limited data exist regarding MG resistance in Israel. Our aim was to study the prevalence of MG resistance in a sexually transmitted infection (STI) clinic in Israel. Methods: We performed a single-center retrospective study among patients attending an STI clinic during 2019–2020. MG isolates were tested to detect their resistance to azithromycin and fluoroquinolones (FQs) using commercial kits (Allplex™ MG & AziR Assay, Allplex™ MG & MoxiR Assay). We collected patient data regarding the risk factors for STIs and resistance. A multivariate logistic regression model was used to identify the risk factors for resistance. Results: Of the 142 patients who tested positive for MG, 50 (35.2%) and 22 (15.5%) had resistant mutations to azithromycin and FQ, respectively, and 13 (9.2%) showed resistance to both agents. In a multivariate logistic regression model, men who have sex with men (RR 7.01 95% CI 3.00–16.33) and past STIs (RR 2.33 95% CI 1.01–5.34) were independent risk factors for azithromycin resistance. Conclusions: We found a high prevalence of azithromycin resistance and, to a lesser degree, FQ resistance. These findings may help design the treatment guidelines and support routine resistance testing in high-risk populations.

26 September 2023 in Diseases
Verified
Journal Article
Open access
PDF file
Abed AgbaryaAbed Agbarya
Abed Agbarya
-S- Ina Sarel
- Ina Sarel
TZTomer Ziv-Baran
Tomer Ziv-Baran
OSOrna Schwartz
Orna Schwartz
YSYelena Shechtman
Yelena Shechtman
RBRonen Brenner
Ronen Brenner
The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response rate of administering the third and fourth vaccine doses to cancer patients receiving active anti-neoplastic treatment. A total of 142 patients received two doses of the mRNA-based BNT162b2 COVID-19 vaccine, while 76 and 25 patients received three and four doses, respectively. The efficacy of the humoral response following two vaccine doses was diminished in cancer patients, especially in the group of patients receiving chemotherapy. In a multivariate analysis, patients who received three and four BNT162b2 vaccine doses were more likely to have antibody titers in the upper tertile compared to patients who received two doses of the vaccine (odds ratio (OR) 7.62 (95% CI 1.38–42.12), p = 0.02 and 17.15 (95% CI 5.01–58.7), p < 0.01, respectively). Unlike the response after two doses, the third and fourth BNT162b2 vaccine booster doses had an increased efficacy of 95–100% in cancer patients while undergoing active treatment. This result could be explained by different mechanisms including the development of memory B cells.

31 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Yasmin MaorYasmin Maor
Yasmin Maor
RARONI AMIR
RONI AMIR
GRGuy Rom
Guy Rom
LSLior Shlomov
Lior Shlomov
ACAssaf Croll
Assaf Croll
IZIris Zohar
Iris Zohar
Purpose: Epidemiology data regarding coronavirus disease 2019 (COVID-19), influenza, and respiratory syncytial virus (RSV) in the Middle East is scarce. We describe hospitalization dynamics and outcomes across these viruses in hospitalized adults. Methods: A retrospective cohort study conducted in a 700-bed hospital in Israel. All hospitalized adults who tested positive for COVID-19, influenza, or RSV between 1 September 2023 and 31 August 2025 were included. Logistic regression models assessed variables associated with mortality. Results: Included were 2201 mono-infected adults (938 COVID-19, 1073 influenza, 190 RSV). COVID-19 demonstrated year-round distribution, whereas influenza and RSV showed seasonality. Invasive ventilation rates were 9.0%, 9.5% and 10.0% in COVID-19, influenza, and RSV patients, respectively. Rates of pneumonia after adjustment were more frequent with influenza. Unadjusted 30- and 90-day mortality were 17.3% and 22.7% for COVID-19, 10.7% and 13.1% for influenza and 18.4% and 21.6% for RSV. In multivariable models, virus type was not significantly associated with 30-day mortality, whereas age, male sex and Charlson comorbidity score were. Conclusions: Influenza and RSV exhibit distinct seasonality, whereas COVID-19 persists year-round, with periodic peaks. Mortality was substantial with all three viruses. These findings add to the understanding of respiratory viruses and support vaccination of older and comorbid adults against all three viruses.

29 August 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
Abed AgbaryaAbed Agbarya
Abed Agbarya
-S- Ina Sarel
- Ina Sarel
TZTomer Ziv-Baran
Tomer Ziv-Baran
OSOrna Schwartz
Orna Schwartz
MAMohammad Sheikh Ahmad
Mohammad Sheikh Ahmad
RBRonen Brenner
Ronen Brenner
The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response of administering the 3rd and 4th vaccine doses to can-cer patients receiving active anti-neoplastic treatment. 142 patients have received two doses of the mRNA-based BNT162b2 COVID-19 vaccine, while 76 and 25 patients have received three and four doses, respectively. The efficacy of the humoral response following two vaccine doses was diminished in cancer patients, especially in the group of patients receiving chemotherapy. In a multivariate analysis, patients after three and four BNT162b2 vaccine doses were more likely to have antibody titers in the upper tertile compared to patients after two doses of the vaccine (odds ratio (OR) 7.62 (95% CI 1.38-42.12), p=0.02 and 17.15 (95% CI 5.01-58.7), p<0.01, respective-ly). Unlike the response after two doses, the 3rd and 4th BNT162b2 vaccine booster doses, had an increased efficacy of 95-100% in cancer patients while on active treatment. This result could be explained by different mechanisms including the development of memory B cells.